{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/V",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "VARIOUS" , "@language" : "en" } ,        { "@value" : "R\u016Fzn\u00E9 p\u0159\u00EDpravky" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "V" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/V03",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "V\u0161echny jin\u00E9 terapeutick\u00E9 p\u0159\u00EDpravky" , "@language" : "cs" } ,        { "@value" : "ALL OTHER THERAPEUTIC PRODUCTS" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "V03" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/V03A",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "V\u0161echny jin\u00E9 terapeutick\u00E9 p\u0159\u00EDpravky" , "@language" : "cs" } ,        { "@value" : "ALL OTHER THERAPEUTIC PRODUCTS" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "V03A" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/V03AN",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Medicin\u00E1ln\u00ED plyny" , "@language" : "cs" } ,        { "@value" : "Medical gases" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "V03AN" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/V03AN01",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/V" ,        "http://linked.opendata.cz/resource/ATC/V03" ,        "http://linked.opendata.cz/resource/ATC/V03A" ,        "http://linked.opendata.cz/resource/ATC/V03AN" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Kysl\u00EDk" , "@language" : "cs" } ,        { "@value" : "OXYGEN" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "V03AN01" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0015671",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Oxygen" , "@language" : "en" } ,        { "@value" : "Kysl\u00EDk" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/CONOXIA--STLACENY-MEDICINALNI-PLYN",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0015671" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125143" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125144" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125145" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125146" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162571" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162572" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0105921" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125142" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125151" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125152" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125153" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125154" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125147" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125148" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125149" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125150" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125159" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125160" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125161" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125162" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125155" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125156" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125157" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125158" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162570" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162571",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "5L/1100L IV" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 5L/1100L IV" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162572",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "5L/1100L V" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 5L/1100L V" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0105921",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/300L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/300L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125142",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/1600L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/1600L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125143",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "40L/6500L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 40L/6500L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125144",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/300L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/300L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125145",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/1600L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/1600L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125146",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "40L/6500L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 40L/6500L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125147",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/400L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/400L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125148",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "5L/1100L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 5L/1100L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125149",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/2200L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/2200L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125150",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "20L/4300L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 20L/4300L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125151",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "50L/10800L I" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 50L/10800L I" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125152",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "50L/10800L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 50L/10800L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125153",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "20L/4300L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 20L/4300L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125154",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/2200L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/2200L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125155",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "5L/1100L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 5L/1100L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125156",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/400L II" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/400L II" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125157",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/400L III" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/400L III" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125158",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/400L IV" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/400L IV" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125159",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "2L/400L V" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 2L/400L V" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125160",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/2200L IV" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/2200L IV" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125161",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10L/2200L V" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 10L/2200L V" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0125162",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "12X50L/129600L VI" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 12X50L/129600L VI" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0162570",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "CONOXIA, STLA\u010CEN\u00DD MEDICIN\u00C1LN\u00CD PLYN" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/V03AN01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "MEDICIN\u00C1LN\u00CD PLYNY" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC151359_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "4.75L/1050L III" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Inhala\u010Dn\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "100%" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : " \nNormobarick\u00E1 oxygenoterapie\nL\u00E9\u010Dba nebo prevence akutn\u00ED nebo chronick\u00E9 hypoxie, bez ohledu na p\u016Fvod.  \nJako sou\u010D\u00E1st anest\u00E9zie nebo intenzivn\u00ED p\u00E9\u010De.\nV\u00A0nebuliza\u010Dn\u00ED terapii.\nL\u00E9\u010Dba akutn\u00EDho z\u00E1chvatu u pacient\u016F se stanovenou diagn\u00F3zou hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache \u2013 Horton\u016Fv syndrom). \nHyperbarick\u00E1 oxygenoterapie \n-   K\u00A0l\u00E9\u010Db\u011B dekompresn\u00ED nemoci, vzduchov\u00E9/plynov\u00E9 embolie jin\u00E9ho p\u016Fvodu a otravy oxidem uhelnat\u00FDm. \nU otravy oxidem uhelnat\u00FDm je hyperbarick\u00E1 oxygenoterapie indikovan\u00E1 nezbytn\u011B u pacient\u016F, kte\u0159\u00ED jsou nebo byli v\u00A0bezv\u011Bdom\u00ED, vykazovali neurologick\u00E9 symptomy, kardiovaskul\u00E1rn\u00ED dysfunkci nebo z\u00E1va\u017Enou acidosu a u t\u011Bhotn\u00FDch \u017Een, u v\u0161ech bez ohledu na jejich COHb.\nJako adjuvantn\u00ED l\u00E9\u010Dba osteoradionekrosy a clostridi\u00E1ln\u00ED myonekrosy (plynat\u00E9 sn\u011Bti). \nZp\u016Fsob pod\u00E1n\u00ED a d\u00E1vkov\u00E1n\u00ED ,\nZp\u016Fsob pod\u00E1n\u00ED\nKysl\u00EDk se pod\u00E1v\u00E1 prost\u0159ednictv\u00EDm vdechovan\u00E9ho vzduchu.\nKysl\u00EDk m\u016F\u017Ee b\u00FDt tak\u00E9 pod\u00E1van\u00FD takzvan\u00FDm oxygen\u00E1torem p\u0159\u00EDmo do krve, mimo jin\u00E9, p\u0159i srde\u010Dn\u00ED chirurgii s\u00A0kardiopulmon\u00E1rn\u00EDm by-pass syst\u00E9mem, a za dal\u0161\u00EDch podm\u00EDnek, kter\u00E9 vy\u017Eaduj\u00ED mimot\u011Bln\u00ED ob\u011Bh.\nKysl\u00EDk je (p\u0159ednostn\u011B) pod\u00E1v\u00E1n prost\u0159ednictv\u00EDm speci\u00E1ln\u00EDho za\u0159\u00EDzen\u00ED. Pomoc\u00ED tohoto za\u0159\u00EDzen\u00ED se kysl\u00EDk pod\u00E1v\u00E1 spole\u010Dn\u011B s\u00A0vdechovan\u00FDm vzduchem a s v\u00FDdechem opou\u0161t\u00ED vydechovan\u00FD plyn s p\u0159ebyte\u010Dn\u00FDm kysl\u00EDkem pacienta a je sm\u00EDch\u00E1n s\u00A0okoln\u00EDm vzduchem (otev\u0159en\u00FD syst\u00E9m).\nP\u0159i anest\u00E9zii, je \u010Dasto pou\u017E\u00EDv\u00E1no speci\u00E1ln\u00ED za\u0159\u00EDzen\u00ED, kdy je vydechovan\u00FD plyn recirkulov\u00E1n a m\u016F\u017Ee b\u00FDt znovu vdechnut. (cirkul\u00E1rn\u00ED syst\u00E9m s\u00A0opakovan\u00FDm d\u00FDch\u00E1n\u00EDm). \nK\u00A0pod\u00E1v\u00E1n\u00ED kysl\u00EDku je ur\u010Deno velk\u00E9 mno\u017Estv\u00ED za\u0159\u00EDzen\u00ED. Za\u0159\u00EDzen\u00ED, jejich\u017E prost\u0159ednictv\u00EDm je kysl\u00EDk pod\u00E1v\u00E1n, by m\u011Bla spl\u0148ovat standardy EU (CE marked).\nN\u00EDzko pr\u016Ftokov\u00E9 syst\u00E9my\nNejjednodu\u0161\u0161\u00ED syst\u00E9my, kter\u00E9 dod\u00E1vaj\u00ED sm\u011Bs kysl\u00EDku a inspirovan\u00E9ho vzduchu, nap\u0159. syst\u00E9m kter\u00FDm je kysl\u00EDk pod\u00E1v\u00E1n jednoduch\u00FDm rotametrem spojen\u00FDm s\u00A0nosn\u00EDm kat\u00E9trem nebo obli\u010Dejovou maskou. \nVysoko pr\u016Ftokov\u00E9 syst\u00E9my\nTyto syst\u00E9my jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce sm\u011Bsi plyn\u016F koresponduj\u00EDc\u00ED s\u00A0\u00FApln\u00FDm vdechovan\u00FDm prost\u0159ed\u00EDm pacienta. Tyto syst\u00E9my  jsou ur\u010Den\u00E9 k\u00A0dod\u00E1vce fixn\u00ED koncentrace kysl\u00EDku, kter\u00E1 nen\u00ED ovlivn\u011Bn\u00E1 \u2013 \u0159ed\u011Bn\u00E1 okoln\u00EDm vzduchem, nap\u0159. Venturiho maska se stabiln\u00EDm pr\u016Ftokem kysl\u00EDku,  tak aby byla pod\u00E1van\u00E1 fixn\u00ED koncentrace kysl\u00EDku ve vdechovan\u00E9m vzduchu.\nHyperbarick\u00E1 oxygenoterapie\nHyperbarick\u00E1 oxygenoterapie (HBO) se aplikuje ve speci\u00E1ln\u011B konstruovan\u00FDch tlakov\u00FDch komor\u00E1ch ur\u010Den\u00FDch k\u00A0l\u00E9\u010Db\u011B hyperbarick\u00FDm kysl\u00EDkem, ve kter\u00FDch mohou b\u00FDt udr\u017Eov\u00E1ny tlaky a\u017E do v\u00FD\u0161e trojn\u00E1sobku atmosf\u00E9rick\u00E9ho tlaku.\nHBO m\u016F\u017Ee b\u00FDt rovn\u011B\u017E aplikov\u00E1na velmi t\u011Bsn\u011B nasedaj\u00EDc\u00ED obli\u010Dejovou maskou, kuklou, kter\u00E1 je t\u011Bsn\u011B kolem hlavy, nebo trache\u00E1ln\u00ED kanylou.\nD\u00E1vkov\u00E1n\u00ED\nSmyslem kysl\u00EDkov\u00E9 terapie je zajistit, \u017Ee parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) nen\u00ED men\u0161\u00ED ne\u017E 8.0 kPa (60\u00A0mmHg) nebo saturace hemoglobinu kysl\u00EDkem v\u00A0arteri\u00E1ln\u00ED krvi nen\u00ED ni\u017E\u0161\u00ED ne\u017E 90\u00A0%, nastaven\u00EDm frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2).  \nD\u00E1vkov\u00E1n\u00ED mus\u00ED b\u00FDt regulov\u00E1no podle pot\u0159eb pacienta. Frakce kysl\u00EDku mus\u00ED b\u00FDt p\u0159izp\u016Fsobena specifick\u00FDm po\u017Eadavk\u016F ka\u017Ed\u00E9ho jednotliv\u00E9ho pacienta vzhledem k\u00A0riziku intoxikace kysl\u00EDkem. (Viz 4.9.)\nV\u0161eobecn\u011B se doporu\u010Duje, \u017Ee nejni\u017E\u0161\u00ED d\u00E1vka FiO2 mus\u00ED b\u00FDt c\u00EDlem k dosa\u017Een\u00ED \u017E\u00E1douc\u00EDch v\u00FDsledk\u016F terapie, bezpe\u010Dn\u00E9ho PaO2. U z\u00E1va\u017En\u00E9 hypoxie by m\u011Bla b\u00FDt ur\u010Dena frakce kysl\u00EDku, kter\u00E9 ji\u017E m\u016F\u017Ee znamenat riziko intoxikace kysl\u00EDkem. \nTerapie mus\u00ED b\u00FDt vyhodnocov\u00E1na kontinu\u00E1ln\u011B a \u00FA\u010Dinek l\u00E9\u010Dby mus\u00ED b\u00FDt m\u011B\u0159en PaO2 nebo alternativn\u011B arteri\u00E1ln\u00ED kysl\u00EDkovou saturac\u00ED (SpO2).\nPro kr\u00E1tkodobou kysl\u00EDkovou terapii mus\u00ED b\u00FDt frakce kysl\u00EDku v\u00A0inspirovan\u00E9m vzduchu (FIO2) (vyvarovat se FiO2 > 0,6 % = 60 % O2 v\u00A0inhalovan\u00E9 sm\u011Bsi plyn\u016F) dr\u017Eena tak, \u017Ee s\u00A0nebo bez pozitivn\u00EDho kone\u010Dn\u00E9ho expira\u010Dn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch  (PEEP)  nebo kontinu\u00E1ln\u00EDho positivn\u00EDho tlaku v\u00A0d\u00FDchac\u00EDch cest\u00E1ch (CPAP) je udr\u017Eov\u00E1n parci\u00E1ln\u00ED arteri\u00E1ln\u00ED tlak kysl\u00EDku (PaO2) > 8 kPa.\nKr\u00E1tkodob\u00E1 kysl\u00EDkov\u00E1 terapie mus\u00ED b\u00FDt monitorov\u00E1na opakovan\u00FDm m\u011B\u0159en\u00EDm arteri\u00E1ln\u00EDch krevn\u00EDch plyn\u016F (PaO2) nebo pulzn\u00ED oximetri\u00ED, kter\u00E1 poskytuje \u010D\u00EDseln\u00E9 hodnoty saturace hemoglobinu kysl\u00EDkem (SpO2). Nicm\u00E9n\u011B, tyto ukazatele m\u011B\u0159\u00ED oxygenaci tk\u00E1n\u00ED jen nep\u0159\u00EDmo. Nejd\u016Fle\u017Eit\u011Bj\u0161\u00ED je klinick\u00E9 zhodnocen\u00ED l\u00E9\u010Dby.\nPro dlouhodobou l\u00E9\u010Dbu by m\u011Bla b\u00FDt pot\u0159eba dodate\u010Dn\u00E9ho kysl\u00EDku ur\u010Dena na z\u00E1klad\u011B z\u00EDskan\u00FDch hodnot krevn\u00EDch plyn\u016F. Krevn\u00ED plyny by m\u011Bly b\u00FDt monitorov\u00E1ny, aby se zamezilo nadbyte\u010Dn\u00E9 retenci oxidu uhli\u010Dit\u00E9ho v\u00A0krvi,  a u pacient\u016F s\u00A0hyperkapni\u00ED terapie kysl\u00EDkem p\u0159izp\u016Fsobena. \nPokud je kysl\u00EDk sm\u00EDch\u00E1n s\u00A0jin\u00FDmi plyny, jeho koncentrace ve sm\u011Bsi inhalovan\u00FDch plyn\u016F (FiO2) mus\u00ED b\u00FDt udr\u017Eov\u00E1na na nejm\u00E9n\u011B 21\u00A0%. Pod\u00EDl kysl\u00EDku m\u016F\u017Ee b\u00FDt zv\u00FD\u0161en a\u017E na 100%.\nNovorozenc\u016Fm m\u016F\u017Ee b\u00FDt pod\u00E1v\u00E1no a\u017E 100% kysl\u00EDku, pokud je to vy\u017Eadov\u00E1no. Nicm\u00E9n\u011B, je nezbytn\u00E9 zajistit pe\u010Dliv\u00FD monitoring pr\u016Fb\u011Bhu l\u00E9\u010Dby. Doporu\u010Duje se vyvarovat se koncentrac\u00EDm kysl\u00EDku p\u0159esahuj\u00EDc\u00EDm 40% , z\u00A0d\u016Fvodu po\u0161kozen\u00ED o\u010Dn\u00ED \u010Do\u010Dky nebo kolapsu plic.\nM\u011Bl by b\u00FDt monitorov\u00E1n tlak kysl\u00EDku v\u00A0arteri\u00E1ln\u00ED krvi (PaO2), riziko po\u0161kozen\u00ED o\u010D\u00ED je sn\u00ED\u017Eeno pokud je (PaO2) udr\u017Eov\u00E1n  pod 13,3 kPa (100\u00A0mmHg), a zabr\u00E1n\u00ED se velk\u00FDm zm\u011Bn\u00E1m v\u00A0oxygenaci.\nK\u00A0indikaci akutn\u00EDho z\u00E1chvatu akutn\u00ED hn\u00EDzdovit\u00E9 bolesti hlavy (cluster headache) by m\u011Bl b\u00FDt kysl\u00EDk pod\u00E1v\u00E1n obli\u010Dejovou maskou v\u00A0otev\u0159en\u00E9m syst\u00E9mu. \nKysl\u00EDkov\u00E1 terapie o pr\u016Ftoku 7 a\u017E 15 l/min. by m\u011Bla b\u00FDt zah\u00E1jena co nejd\u0159\u00EDve po vzniku ataky a m\u011Bla by trvat asi 15 minut nebo dokud bolest nep\u0159ejde. Obvykle je dostate\u010Dn\u00FD pr\u016Ftok 7 a\u017E 10 l/ min., ale u n\u011Bkter\u00FDch pacient\u016F je nutn\u00FD k\u00A0dosa\u017Een\u00ED \u00FA\u010Dinku pr\u016Ftok a\u017E do 15 l / min. \nHyperbarick\u00E1 oxygenace (HBO) znamen\u00E1 pod\u00E1v\u00E1n\u00ED 100% kysl\u00EDku p\u0159i tlaku nad 1.4 n\u00E1sobkem atmosf\u00E9rick\u00E9ho tlaku u\u00A0hladiny mo\u0159e (1 atmosf\u00E9ra = 101,.3 kPa = 760\u00A0mmHg). Z\u00A0bezpe\u010Dnostn\u00EDch d\u016Fvod\u016F by tlak pou\u017E\u00EDvan\u00FD v HBO nem\u011Bl p\u0159es\u00E1hnout 3 atmosf\u00E9ry. \nTrv\u00E1n\u00ED jedn\u00E9 terapie HBO p\u0159i tlaku 2 a\u017E 3 atmosf\u00E9ry se pohybuje mezi 60 minutami a 4 - 6 hodinami v\u00A0z\u00E1vislosti na indikaci. Pokud je to nutn\u00E9, l\u00E9\u010Dba m\u016F\u017Ee b\u00FDt opakov\u00E1na 2 kr\u00E1t a\u017E 3 kr\u00E1t denn\u011B, v\u00A0z\u00E1vislosti na indikaci a klinick\u00E9m stavu pacienta. V\u00EDcen\u00E1sobn\u00E1 terapie je \u010Dasto nezbytn\u00E1 k\u00A0l\u00E9\u010Db\u011B infekc\u00ED m\u011Bkk\u00FDch tk\u00E1n\u00ED a hypoxick\u00FDch ran, kter\u00E9 neodpov\u00EDdaj\u00ED na obvyklou tradi\u010Dn\u00ED l\u00E9\u010Dbu.  \nHBO by m\u011Bla b\u00FDt pod\u00E1v\u00E1na person\u00E1lem kvalifikovan\u00FDm pro tuto l\u00E9\u010Dbu. \nKomprese a dekomprese by m\u011Bla b\u00FDt pomal\u00E1, v\u00A0souladu s\u00A0b\u011B\u017Enou prax\u00ED, aby se zabr\u00E1nilo riziku po\u0161kozen\u00ED tlakem (barotrauma).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "INH GAS 4.75L/1050L III" , "@language" : "cs" } ] }] }